Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1761. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer.

Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin. On this basis, we did an open-label study in which oral gabapentin 300 mg thrice daily was given for every other chemotherapy treatment in nine patients with breast cancer. Six of the nine reported at least a three-point improvement in peak

Lancet2003

1762. Gene expression predictors of breast cancer outcomes.

Gene expression predictors of breast cancer outcomes. BACKGROUND: Correlation of risk factors with genomic data promises to provide specific treatment for individual patients, and needs interpretation of complex, multivariate patterns in gene expression data, as well as assessment of their ability to improve clinical predictions. We aimed to predict nodal metastatic states and relapse for breast cancer patients. METHODS: We analysed DNA microarray data from samples of primary breast tumours (...) different biological processes underlying these two characteristics of breast cancer. Initial external validation came from similarly accurate predictions of nodal status of a small sample in a distinct population. INTERPRETATION: Multiple aggregate measures of profiles of gene expression define valuable predictive associations with lymph node metastasis and disease recurrence for individual patients. Gene expression data have the potential to aid accurate, individualised, prognosis. Importantly

Lancet2003

1763. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening.

Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. BACKGROUND: The long term effect of mammographic service screening is not well established. We aimed to assess the long-term effect of mammographic screening on death from breast cancer, taking into account potential biases from self-selection, changes in breast cancer incidence, and classification of cause of death. METHODS: We compared deaths from breast cancer (...) diagnosed in the 20 years before screening was introduced (1958-77) with those from breast cancer diagnosed in the 20 years after the introduction of screening (1978-97) in two Swedish counties, in 210000 women aged 20-69 years. We also compared deaths from all cancers and from all causes in patients diagnosed with breast cancer in the 20 years before and after screening was introduced. In the analysis, data were stratified into age-groups invited for screening (40-69 years) and not invited (20-39 years

Lancet2003

1764. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history.

Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. We aimed to assess frequency and penetrance of BRCA1, BRCA2,and TP53 mutations in women diagnosed with breast cancer aged 30 years or younger, and then correlate this frequency with family history. 17 of 36 familial cases had a BRCA1, BRCA2, or TP53 mutation, compared with three of 63 non-familial cases. The calculated population frequency of TP53 mutations was one in 5000, substantially greater (...) than previous estimates. This finding underlines the importance of accurate elucidation of a family history from young women diagnosed with breast cancer. Establishment of family history could help with development of patient-specific management and tumour surveillance protocols.

Lancet2003

1765. Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort.

Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort. OBJECTIVE: To investigate whether size at birth and rate of fetal growth influence the risk of breast cancer in adulthood. DESIGN: Cohort identified from detailed birth records, with 97% follow up. SETTING: Uppsala Academic Hospital, Sweden. PARTICIPANTS: 5358 singleton females born during 1915-29, alive and traced to the 1960 census. MAIN OUTCOME MEASURES: Incidence of breast cancer before (...) (at age <50 years) and after (> or = 50 years) the menopause. RESULTS: Size at birth was positively associated with rates of breast cancer in premenopausal women. In women who weighed > or =4000 g at birth rates of breast cancer were 3.5 times (95% confidence interval 1.3 to 9.3) those in women of similar gestational age who weighed <3000 g at birth. Rates in women in the top fifths of the distributions of birth length and head circumference were 3.4 (1.5 to 7.9) and 4.0 (1.6 to 10.0

BMJ2003 Full Text: Link to full Text with Trip Pro

1766. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.

Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. BACKGROUND: Although the efficacy of adjuvant chemotherapy in prolonging survival for women with breast cancer has been well documented, limited population-based information is available on the actual use of chemotherapy. OBJECTIVE: To examine the relationship between age and chemotherapy use. DESIGN: Cohort study. SETTING: New Mexico. PATIENTS: 5101 women 20 years of age (...) or older receiving a diagnosis of stage I, stage II, or stage IIIA breast cancer from 1991 through 1997. MEASUREMENTS: Pattern of chemotherapy use by age; logistic regression analysis to generate the odds and probabilities of receiving chemotherapy; and sensitivity analysis to estimate potential effects of unmeasured confounders. RESULTS: Overall, 29% of women received chemotherapy. The rate of chemotherapy use for women with stage I, stage II, or stage IIIA breast cancer was 11%, 47%, and 68

Annals of Internal Medicine2003 Full Text: Link to full Text with Trip Pro

1767. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study.

Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. BACKGROUND: Clinical decisions about atypical lobular hyperplasia are based on the belief that later invasive breast-cancer risk is equal in both breasts. We aimed to show laterality and subsequent risk implications of invasive breast cancer in women with atypical lobular hyperplasia. METHODS: We did a retrospective cohort study of 252 women who had undergone 261 benign surgical biopsies (...) that showed atypical lobular hyperplasia from 1950 to 1985, as part of the Nashville Breast Studies. Primary outcomes were development of invasive breast cancer and laterality of cancer compared with side of the biopsied breast. FINDINGS: 50 (20%) of 252 women treated by biopsy only developed invasive breast cancer. Relative risk of breast cancer in women with atypical lobular hyperplasia was 3.1 (95% CI 2.3-4.3, p<0.0001). Of these 50 women, the breast with invasive cancer was the same breast

Lancet2003

1768. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer

Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(15). 2003 Authors

Health Technology Assessment (HTA) Database.2003

1769. FDG positron emission tomography for evaluating breast cancer

FDG positron emission tomography for evaluating breast cancer FDG positron emission tomography for evaluating breast cancer FDG positron emission tomography for evaluating breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 (...) years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. FDG positron emission tomography for evaluating breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(14). 2003 Authors' objectives This Assessment updates the 2001 TEC Assessment on FDG PET imaging for evaluating breast cancer (Vol. 16, No. 5). This Assessment is organized into 3 parts, as follows: Part I: Initial Staging

Health Technology Assessment (HTA) Database.2003

1770. The role of the taxanes in the management of metastatic breast cancer

The role of the taxanes in the management of metastatic breast cancer The role of the taxanes in the management of metastatic breast cancer The role of the taxanes in the management of metastatic breast cancer Verma S, Trudeau M, Pritchard K, Oliver T, Breast Cancer Disease Site Group CRD summary The authors recommended the use of docetaxel with or without doxorubicin for women who have never previously received anthracyclines, and docetaxel or paclitaxel treatment for those with prior (...) anthracycline use. The poor reporting of review methods and lack of a quality assessment make it difficult to assess the reliability of the authors' conclusions. Authors' objectives To assess the role of taxanes in the management of metastatic breast cancer. In particular, to assess paclitaxel or docetaxel delivered as monotherapy, or in combination with other agents, in patients with no previous anthracycline exposure; and single-agent paclitaxel or docetaxel in patients with prior anthracycline exposure

DARE.2003

1771. Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature

Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature Liberman M, Sampalis F, Mulder D S, Sampalis J S CRD summary This diagnostic review combined studies of scintimammography in different patient populations, and which used different methods of establishing the true diagnosis (...) . The authors concluded that scintimammography would be useful as an additional test in patients with indeterminate mammogram results. The view has a number of methodological weaknesses and the evidence presented does not support the general conclusion. Authors' objectives To assess the performance of scintimammography in the diagnosis of breast cancer. Searching MEDLINE was searched from 1967 to 1999 for articles in English, using the keyword 'scintimammography'. The reference sections of retrieved papers

DARE.2003

1772. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen

Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen Dranitsaris G, Verma S, Trudeau M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of hormonal agents, the aromatase inhibitors letrozole and anastrozole, as first-line treatment of hormone-sensitive breast cancer in postmenopausal women. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population

NHS Economic Evaluation Database.2003

1773. Identifying the optimal timing of HER2 testing in patients with breast cancer: a Canadian economic evaluation

Identifying the optimal timing of HER2 testing in patients with breast cancer: a Canadian economic evaluation Identifying the optimal timing of HER2 testing in patients with breast cancer: a Canadian economic evaluation Identifying the optimal timing of HER2 testing in patients with breast cancer: a Canadian economic evaluation Dranitsaris G, Norris B, Hanna W, O'Malley F, Gelmon K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Testing for human epidermal growth factor receptor 2 (HER2) in patients with stages I - III breast cancer was examined. The testing procedure entailed an initial immunohistochemistry (IHC) test, followed by a fluorescent in situ hybridisation (FISH) test if the IHC test results were

NHS Economic Evaluation Database.2003

1774. The benefits and costs of tamoxifen for breast cancer prevention

The benefits and costs of tamoxifen for breast cancer prevention The benefits and costs of tamoxifen for breast cancer prevention The benefits and costs of tamoxifen for breast cancer prevention Eckermann S D, Martin A J, Stockler M R, Simes R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of tamoxifen therapy for 5 years, relative to placebo, for the prevention of breast cancer. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised women with a high risk of breast cancer. The cohort of women that was simulated in the model had the same baseline distribution as those enrolled in the NSA BP-1 trial (see Other Publications of Related

NHS Economic Evaluation Database.2003

1775. Economic evaluation of breast cancer treatment: considering the value of patient choice

Economic evaluation of breast cancer treatment: considering the value of patient choice Economic evaluation of breast cancer treatment: considering the value of patient choice Economic evaluation of breast cancer treatment: considering the value of patient choice Polsky D, Mandelblatt J S, Weeks J C, Venditti L, Hwang Y T, Glick H A, Hadley J, Schulman K A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Alternative breast cancer treatments, that is, breast-conserving surgery with radiation (BCSRT) versus mastectomy, were examined. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised women aged 65 years or older receiving a diagnosis of early-stage breast

NHS Economic Evaluation Database.2003

1776. Cost utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer

Cost utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer Cost utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer Cost utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer Martin S C, Gagnon D D, Zhang L, Bokemeyer C, Van Marwijk Kooy M, van Hout B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The comparison of epoetin-alpha, a recombinant human erythropoietin, with placebo among patients with Stage IV breast cancer. Type of intervention Palliative care. Economic study type Cost-utility analysis. Study population To be included in the original study by Littlewood et al. (see Other Publications of Related Interest

NHS Economic Evaluation Database.2003

1777. The safety net: a cost-effective approach to improving breast and cervical cancer screening

The safety net: a cost-effective approach to improving breast and cervical cancer screening The safety net: a cost-effective approach to improving breast and cervical cancer screening The safety net: a cost-effective approach to improving breast and cervical cancer screening Vogt T M, Glass A, Glasgow R E, La Chance P A, Lichtenstein E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) systems, but no intervention was delivered beyond routine system and environmental reminders. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population comprised women unscreened for breast and cervical cancer for at least 3 years, and who had been part of the Northwest Kaiser Permanente (NWKP) managed care organisation for 3 years or more. Women in the mammography trial were aged 40 to 70 years, while women in the Pap smear study were aged

NHS Economic Evaluation Database.2003

1778. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer

Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer Verma S, Rocchi A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of anastrozole, exemestane, letrozole and megesterol for the second-line treatment of metastatic breast cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of 1,000 65-year-old women with metastatic breast cancer who had failed tamoxifen. Setting

NHS Economic Evaluation Database.2003

1779. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer

Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer Verma S, Ilersich A L Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of capecitabine (Xeloda; Hoffman-La Roche)-docetaxel combination therapy for the treatment of anthracycline-pretreated metastatic breast cancer (MBC). The regime used was 21-day cycles of oral

NHS Economic Evaluation Database.2003

1780. The management of the woman with metastatic breast cancer: a guide for GPs

The management of the woman with metastatic breast cancer: a guide for GPs Cancer Australia | A national government agency working to reduce the impact of cancer on all Australians ") //--> ") //--> Search form Search News Featured Sites Featured Video Visit our channel Video of Introduction to the Statement View the video transcript ( ) Cancer types A - Z list of cancer types In Focus Copyright © 2017 - Cancer Australia

National Breast and Ovarian Cancer Centre2003